Review
. 2022 Apr 27;7(3):e1005.
doi: 10.1097/PR9.0000000000001005.
eCollection May-Jun 2022.
Affiliations
Affiliations
- 1 Department of Anesthesiology, Zealand University Hospital,Denmark.
- 2 Institution of Health Sciences, Lund University, Lund, Sweden.
- 3 Department of Surgical Sciences, Plastic Surgery, Akademiska University Hospital Uppsala, Uppsala, Sweden.
- 4 Copenhagen Spine Research Unit (CSRU), Section of Spine Surgery, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.
Item in Clipboard
Review
Anja Geisler et al.
Pain Rep.
.
Display options
Format
. 2022 Apr 27;7(3):e1005.
doi: 10.1097/PR9.0000000000001005.
eCollection May-Jun 2022.
Affiliations
- 1 Department of Anesthesiology, Zealand University Hospital,Denmark.
- 2 Institution of Health Sciences, Lund University, Lund, Sweden.
- 3 Department of Surgical Sciences, Plastic Surgery, Akademiska University Hospital Uppsala, Uppsala, Sweden.
- 4 Copenhagen Spine Research Unit (CSRU), Section of Spine Surgery, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.
Item in Clipboard
Display options
Format
Abstract
Patients undergoing spinal surgery are at high risk of acute and persistent postoperative pain. Therefore, adequate pain relief is crucial. This systematic review aimed to provide answers about best-proven postoperative analgesic treatment for patients undergoing lumbar 1- or 2-level fusions for degenerative spine diseases. We performed a search in PubMed, Embase, and The Cochrane Library for randomized controlled trials. The primary outcome was opioid consumption after 24 hours postoperatively. We performed meta-analyses, trial sequential analyses, and Grading of Recommendations assessment to accommodate systematic errors. Forty-four randomized controlled trials were included with 2983 participants. Five subgroups emerged: nonsteroidal anti-inflammatory drugs (NSAIDs), epidural, ketamine, local infiltration analgesia, and intrathecal morphine. The results showed a significant reduction in opioid consumption for treatment with NSAID (P < 0.0008) and epidural (P < 0.0006) (predefined minimal clinical relevance of 10 mg). Concerning secondary outcomes, significant reductions in pain scores were detected after 6 hours at rest (NSAID [P < 0.0001] and intrathecal morphine [P < 0.0001]), 6 hours during mobilization (intrathecal morphine [P = 0.003]), 24 hours at rest (epidural [P < 0.00001] and ketamine [P < 0.00001]), and 24 hours during mobilization (intrathecal morphine [P = 0.03]). The effect of wound infiltration was nonsignificant. The quality of evidence was low to very low for most trials. The results from this systematic review showed that some analgesic interventions have the capability to reduce opioid consumption compared with control groups. However, because of the high risk of bias and low evidence, it was impossible to recommend a “gold standard” for the analgesic treatment after 1- or 2-level spinal fusion surgery.
Keywords:
Analgesics; Pain; Pain treatment; Spinal fusion.
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain.
Conflict of interest statement
The authors have no conflicts of interest to declare.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Cite